An accelerated dose escalation with a grass pollen allergoid is safe and well-tolerated: a randomized open label phase II trial
Crossref DOI link: https://doi.org/10.1186/s13601-016-0093-z
Published Online: 2016-02-02
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Chaker, A. M.
Al-Kadah, B.
Luther, U.
Neumann, U.
Wagenmann, M.
Funding for this research was provided by:
This study was a sponsored clinical trial and funded by Allergopharma GmbH & Co. KG (Reinbek, Germany).